Article Details
Retrieved on: 2024-03-14 15:25:26
Tags for this article:
Click the tags to see associated articles and topics
Summary
First Wave BioPharma, a biopharma company trading as a penny stock on NASDAQ, saw increased stock market volume after acquiring ImmunogenX, advancing a potential celiac disease treatment towards Phase 3 trials.
Article found on: investorplace.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here